BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 11381366)

  • 21. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
    Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
    Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
    Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
    Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
    Gursan N; Karakök M; Sari I; Gursan MS
    Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast.
    Tan PH; Chuah KL; Chiang G; Wong CY; Dong F; Bay BH
    Oncol Rep; 2002; 9(5):1081-6. PubMed ID: 12168077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.